Abbott Laboratories (ABT) Competitors $132.76 +1.43 (+1.09%) Closing price 03:59 PM EasternExtended Trading$133.22 +0.46 (+0.35%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABT vs. DXCM, ISRG, TSLA, ABBV, BSX, ELV, ITGR, JNJ, MDT, and TMOShould you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include DexCom (DXCM), Intuitive Surgical (ISRG), Tesla (TSLA), AbbVie (ABBV), Boston Scientific (BSX), Elevance Health (ELV), Integer (ITGR), Johnson & Johnson (JNJ), Medtronic (MDT), and Thermo Fisher Scientific (TMO). Abbott Laboratories vs. Its Competitors DexCom Intuitive Surgical Tesla AbbVie Boston Scientific Elevance Health Integer Johnson & Johnson Medtronic Thermo Fisher Scientific Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability. Which has more risk and volatility, ABT or DXCM? Abbott Laboratories has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Do institutionals & insiders believe in ABT or DXCM? 75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ABT or DXCM more profitable? Abbott Laboratories has a net margin of 32.43% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Abbott Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Abbott Laboratories32.43% 18.32% 10.71% DexCom 13.29%30.41%10.08% Do analysts recommend ABT or DXCM? Abbott Laboratories presently has a consensus price target of $144.47, indicating a potential upside of 8.82%. DexCom has a consensus price target of $99.89, indicating a potential upside of 30.50%. Given DexCom's higher possible upside, analysts clearly believe DexCom is more favorable than Abbott Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abbott Laboratories 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.91DexCom 0 Sell rating(s) 5 Hold rating(s) 14 Buy rating(s) 3 Strong Buy rating(s) 2.91 Does the media refer more to ABT or DXCM? In the previous week, Abbott Laboratories had 19 more articles in the media than DexCom. MarketBeat recorded 54 mentions for Abbott Laboratories and 35 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.57 beat DexCom's score of 1.21 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 51 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DexCom 23 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, ABT or DXCM? Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbott Laboratories$41.95B5.51$13.40B$7.9816.64DexCom$4.03B7.44$576.20M$1.4453.16 SummaryAbbott Laboratories beats DexCom on 9 of the 16 factors compared between the two stocks. Get Abbott Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABT vs. The Competition Export to ExcelMetricAbbott LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$228.57B$10.84B$5.73B$21.51BDividend Yield1.80%1.89%5.90%3.50%P/E Ratio16.6421.3875.8629.83Price / Sales5.5129.21528.7453.44Price / Cash19.9524.4737.1724.76Price / Book4.813.4312.794.53Net Income$13.40B$212.47M$3.28B$998.53M7 Day Performance0.55%-1.00%0.22%1.07%1 Month Performance0.84%2.17%4.61%4.41%1 Year Performance12.86%-10.93%68.33%14.45% Abbott Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABTAbbott Laboratories4.9087 of 5 stars$132.76+1.1%$144.47+8.8%+12.9%$228.57B$41.95B16.64114,000Positive NewsDXCMDexCom4.9754 of 5 stars$80.05-0.9%$99.89+24.8%+8.7%$31.41B$4.03B55.6210,300Positive NewsISRGIntuitive Surgical4.9481 of 5 stars$464.19+2.1%$595.95+28.4%-11.4%$166.57B$8.35B64.8115,638Trending NewsAnalyst RevisionTSLATesla4.2555 of 5 stars$347.50+2.6%$303.31-12.7%+78.1%$1.12T$97.69B200.98125,665Trending NewsAnalyst ForecastABBVAbbVie4.7904 of 5 stars$212.51-0.2%$214.95+1.2%+12.2%$374.88B$56.33B101.0555,000Trending NewsAnalyst ForecastAnalyst RevisionBSXBoston Scientific4.8367 of 5 stars$107.44+0.1%$117.50+9.4%+19.7%$159.12B$16.75B63.9253,000Positive NewsOptions VolumeELVElevance Health4.8801 of 5 stars$311.23+1.0%$411.06+32.1%-44.3%$70.18B$177.01B13.26104,200ITGRInteger3.9456 of 5 stars$106.73+0.1%$140.25+31.4%-21.0%$3.74B$1.72B47.0511,000Positive NewsJNJJohnson & Johnson4.683 of 5 stars$178.84+0.0%$176.29-1.4%+7.2%$430.47B$88.82B19.12138,100Trending NewsAnalyst UpgradeMDTMedtronic4.9418 of 5 stars$93.26+0.4%$102.14+9.5%+3.9%$119.49B$33.54B25.6695,000Positive NewsTMOThermo Fisher Scientific4.9628 of 5 stars$493.14+0.7%$589.38+19.5%-22.3%$186.28B$42.88B28.53125,000Positive News Related Companies and Tools Related Companies DXCM Alternatives ISRG Alternatives TSLA Alternatives ABBV Alternatives BSX Alternatives ELV Alternatives ITGR Alternatives JNJ Alternatives MDT Alternatives TMO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABT Stock Alerts